Tags

Type your tag names separated by a space and hit enter

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
J Am Acad Dermatol. 2018 02; 78(2):383-394.JA

Abstract

BACKGROUND

There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD.

OBJECTIVE

To assess therapeutic options for patients with psoriasis and concurrent IBD.

METHODS

A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected.

RESULTS

Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn's disease. Etanercept, secukinumab, brodalumab, and ixekizumab have demonstrated efficacy in psoriasis and psoriatic arthritis but may exacerbate or induce IBD. Guselkumab has demonstrated efficacy in psoriasis.

LIMITATIONS

There are no known clinical trials of treatment specifically for concurrent psoriasis and IBD.

CONCLUSIONS

Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Whitlock SM
Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia.
Enos CW
Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia.
Armstrong AW
Department of Dermatology, University of Southern California, Los Angeles, California.
Gottlieb A
Department of Medicine, New York Medical College, Valhalla, New York.
Langley RG
Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, Canada.
Lebwohl M
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Merola JF
Department of Dermatology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
Ryan C
Division of Dermatology, Baylor University Medical Center, Dallas, Texas.
Siegel MP
National Psoriasis Foundation, Portland, Oregon.
Weinberg JM
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Wu JJ
Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.
Van Voorhees AS
Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia. Electronic address: vanvooas@evms.edu.

MeSH

AcitretinAdalimumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCertolizumab PegolCyclosporineDermatologic AgentsEtanerceptGastrointestinal AgentsHumansInflammatory Bowel DiseasesInfliximabPsoriasisThalidomideUstekinumab

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29332708

Citation

Whitlock, Scott M., et al. "Management of Psoriasis in Patients With Inflammatory Bowel Disease: From the Medical Board of the National Psoriasis Foundation." Journal of the American Academy of Dermatology, vol. 78, no. 2, 2018, pp. 383-394.
Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383-394.
Whitlock, S. M., Enos, C. W., Armstrong, A. W., Gottlieb, A., Langley, R. G., Lebwohl, M., Merola, J. F., Ryan, C., Siegel, M. P., Weinberg, J. M., Wu, J. J., & Van Voorhees, A. S. (2018). Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology, 78(2), 383-394. https://doi.org/10.1016/j.jaad.2017.06.043
Whitlock SM, et al. Management of Psoriasis in Patients With Inflammatory Bowel Disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383-394. PubMed PMID: 29332708.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. AU - Whitlock,Scott M, AU - Enos,Clinton W, AU - Armstrong,April W, AU - Gottlieb,Alice, AU - Langley,Richard G, AU - Lebwohl,Mark, AU - Merola,Joseph F, AU - Ryan,Caitriona, AU - Siegel,Michael P, AU - Weinberg,Jeffrey M, AU - Wu,Jashin J, AU - Van Voorhees,Abby S, PY - 2017/02/20/received PY - 2017/06/13/revised PY - 2017/06/20/accepted PY - 2018/1/16/entrez PY - 2018/1/16/pubmed PY - 2018/7/24/medline KW - Crohn's disease KW - IBD KW - inflammatory bowel disease KW - psoriasis KW - psoriatic arthritis KW - ulcerative colitis SP - 383 EP - 394 JF - Journal of the American Academy of Dermatology JO - J Am Acad Dermatol VL - 78 IS - 2 N2 - BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected. RESULTS: Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn's disease. Etanercept, secukinumab, brodalumab, and ixekizumab have demonstrated efficacy in psoriasis and psoriatic arthritis but may exacerbate or induce IBD. Guselkumab has demonstrated efficacy in psoriasis. LIMITATIONS: There are no known clinical trials of treatment specifically for concurrent psoriasis and IBD. CONCLUSIONS: Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications. SN - 1097-6787 UR - https://www.unboundmedicine.com/medline/citation/29332708/Management_of_psoriasis_in_patients_with_inflammatory_bowel_disease:_From_the_Medical_Board_of_the_National_Psoriasis_Foundation_ DB - PRIME DP - Unbound Medicine ER -